Search results
Results from the WOW.Com Content Network
It is stimulated by decreased O 2 in circulation, which is detected by the kidneys, which then secrete the hormone erythropoietin. [2] This hormone stimulates proliferation and differentiation of red cell precursors, which activates increased erythropoiesis in the hemopoietic tissues, ultimately producing red blood cells (erythrocytes). [2]
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1] [2] In these situations they decrease the need for blood transfusions. [2]
Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n,-r ə-,-p ɔɪ ˈ ɛ t ɪ n,-ˈ iː t ɪ n /; [1] [2] [3] EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow.
[8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10]
Erythropoiesis-stimulating agents are only recommended in those with severe anemia. [10] Anemia is the most common blood disorder, affecting about a fifth to a third of the global population. [1] [11] [12] [13] Iron-deficiency anemia is the most common cause of anemia worldwide, and affects nearly one billion people. [14]
The growth of CFU-GEMM is stimulated by the stem cell factor, or SCF. SCF has been found also to synergize with GM-CSF, IL-6, IL-3, IL-11 or erythropoietin to increase the numbers of CFU-GEMM. [6] CFU-GEMM gives rise to CFU-GM (leading to monoblasts and myeloblasts), CFU-Meg (leading to megakaryoblasts), and CFU-E (leading to proerythroblasts).
It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
Erythropoietin (EPO) is a hormone that stimulates erythropoiesis, which can also be given as a medicine to increase the hemoglobin content of the blood, but EPO is not classified as a hematinic as it is not considered a nutrient, but a hormone.